Biocryst Pharmaceuticals (BCRX) EBT Margin (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) posted EBT Margin of 460.84% for Q1 2026, down 101.32% on a QoQ basis from 35030.65% in Q4 2025, and down 46136.0% year-over-year from N/an in Q1 2025.
Biocryst Pharmaceuticals (BCRX) EBT Margin (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' EBT Margin history runs 17 years deep, the most recent figure standing at 460.84% for Q1 2026.
- Quarterly EBT Margin fell 46136.0% year-over-year to 460.84% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 94.65% (down 8448.0% YoY) and the FY2025 annual result came in at 30.56%, up 4986.0% from the prior year.
- EBT Margin was 460.84% for Q1 2026 at Biocryst Pharmaceuticals, down from 35030.65% in the prior quarter.
- Across five years, EBT Margin topped out at 35030.65% in Q4 2025 and bottomed at 460.84% in Q1 2026.
- A 5-year average of 1990.89% and a median of 41.29% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2025 — EBT Margin soared 3505041 bps — and 2026, when it tumbled 46136 bps.
- Biocryst Pharmaceuticals' EBT Margin stood at 89.84% in 2022, then increased by 25 bps to 67.62% in 2023, then surged by 71 bps to 19.76% in 2024, then soared by 177381 bps to 35030.65% in 2025, then slumped by 101 bps to 460.84% in 2026.
- Business Quant data shows BCRX's EBT Margin at 460.84% in Q1 2026, 35030.65% in Q4 2025, and 7.61% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 10.97% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 33.51% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -41.57% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 40.73% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -7.05% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 30.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.35% |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -460.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -460.84% |
| Dec 31, 2025 | 35,030.65% |
| Sep 30, 2025 | 7.61% |
| Jun 30, 2025 | 3.97% |
| Mar 31, 2025 | 0.52% |
| Dec 31, 2024 | -19.76% |
| Sep 30, 2024 | -11.48% |
| Jun 30, 2024 | -11.43% |
| Mar 31, 2024 | -37.75% |
| Dec 31, 2023 | -67.62% |
| Sep 30, 2023 | -41.29% |
| Jun 30, 2023 | -90.42% |
| Mar 31, 2023 | -76.57% |
| Dec 31, 2022 | -89.84% |
| Sep 30, 2022 | -54.07% |
| Jun 30, 2022 | -88.51% |
| Mar 31, 2022 | -148.06% |
| Dec 31, 2021 | -32.92% |
| Sep 30, 2021 | -143.44% |
| Jun 30, 2021 | -86.47% |